

May 25, 2016



Cocrystal Pharma to Present at Jefferies 2016 Healthcare Conference

Cocrystal CEO & CMO to Present Thursday, June 9, 2016, 8:30 AM ET in NYC

BOTHELL, WA and ATLANTA, GA -- (Marketwired) -- 05/25/16 -- Cocrystal Pharma, Inc. (OTCQB: COCP), a clinical stage company focused on developing novel antiviral therapeutics for human viral diseases, announced today that it will be presenting at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016. Jeffrey Meckler, Chief Executive Officer, and Douglas Mayers, Chief Medical Officer, will make a formal presentation on the Company from 8:30 to 9:00 am ET. A live webcast of the presentation can be accessed from the conference website at <http://wsw.com/webcast/jeff97/cocp>. An archived edition of the presentation will be available on the Cocrystal website, www.cocrystalpharma.com, shortly after the event.

About Cocrystal Pharma

Cocrystal is a clinical stage biotechnology company seeking to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Cocrystal employs unique technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. These technologies, including our nucleoside chemistry expertise and market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer. The company has identified promising, preclinical and clinical stage antiviral compounds for several unmet medical needs, including hepatitis, influenza and norovirus infections. Cocrystal has previously received strategic investments from Teva Pharmaceuticals, OPKO Health (NYSE: OPK), Brace Pharmaceutical, LLC, and The Frost Group. For further information about Cocrystal, please refer to www.cocrystalpharma.com.

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Cocrystal, they are forward-looking statements reflecting the current beliefs and expectations of management including statements regarding development plans for antiviral drugs. Forward-looking statements in this release involve substantial risks and uncertainties that could cause or clinical development programs, performance or future results to differ significantly from what is expressed or implied by the forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Cocrystal has made with the Securities and Exchange Commission.

Contact:

MDM Worldwide
David Zazoff
212-643-0417

Source: Cocrystal Pharma, Inc.